NASDAQ:GOVX GeoVax Labs (GOVX) Stock Forecast, Price & News $0.57 +0.05 (+9.69%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$0.52▼$0.6050-Day Range$0.51▼$0.6252-Week Range$0.51▼$1.39Volume1.07 million shsAverage Volume838,122 shsMarket Capitalization$14.97 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media GeoVax Labs MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside783.4% Upside$5.00 Price TargetShort InterestHealthy2.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 5 Articles This WeekInsider TradingAcquiring Shares$30,219 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.64) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector154th out of 975 stocksPharmaceutical Preparations Industry51st out of 453 stocks 3.5 Analyst's Opinion Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, GeoVax Labs has a forecasted upside of 783.4% from its current price of $0.57.Amount of Analyst CoverageGeoVax Labs has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.56% of the outstanding shares of GeoVax Labs have been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 14.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GOVX. Previous Next 3.2 News and Social Media Coverage News SentimentGeoVax Labs has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GeoVax Labs this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for GOVX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,219.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($0.64) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeoVax Labs is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeoVax Labs is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GeoVax Labs (NASDAQ:GOVX) StockGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More GOVX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVX Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming October Investor and Industry EventsSeptember 26, 2023 | markets.businessinsider.comGeoVax Labs Secures License Agreement With ProBioGenOctober 2, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 19, 2023 | finance.yahoo.comGeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised PatientsSeptember 12, 2023 | finance.yahoo.comGeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 11, 2023 | finance.yahoo.comGeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine BoosterAugust 31, 2023 | msn.comGeovax Labs (GOVX) Price Target Increased by 11.11% to 6.12August 31, 2023 | finance.yahoo.comGeoVax to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceOctober 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 28, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Receives Notice of Allowance for Malaria Vaccine PatentAugust 11, 2023 | finance.yahoo.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call TranscriptJuly 26, 2023 | finance.yahoo.comGeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023July 24, 2023 | markets.businessinsider.comGeoVax Labs (GOVX) Gets a Buy from Noble FinancialJuly 24, 2023 | finance.yahoo.comGeoVax Announces Issuance of Ebola Vaccine PatentJuly 20, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaJuly 20, 2023 | finance.yahoo.comGeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaJune 28, 2023 | finance.yahoo.comGeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer ConferenceJune 27, 2023 | finance.yahoo.comGeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine InsightsMay 31, 2023 | finance.yahoo.comGeoVax Partners With ABL to Advance cGMP Production of Vaccine CandidatesMay 25, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming Industry MeetingsMay 24, 2023 | msn.comGeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising ResultsMay 15, 2023 | finance.yahoo.comGeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific MeetingsMay 9, 2023 | marketwatch.comGeoVax Labs to Participate in A.G.P.'s Virtual Healthcare ConferenceMay 9, 2023 | msn.comNoble Capital Markets Initiates Coverage of Geovax Labs (GOVX) with Outperform RecommendationMay 9, 2023 | msn.comHC Wainwright & Co. Reiterates Geovax Labs (GOVX) Buy RecommendationMay 4, 2023 | msn.comGeovax Labs: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comGeoVax Reports 2023 First Quarter Financial Results and Provides Corporate UpdateSee More Headlines Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address GOVX Company Calendar Last Earnings8/09/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOVX CUSIPN/A CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees14Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+802.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,020,000.00 Net MarginsN/A Pretax Margin-1,931,699.75% Return on Equity-79.25% Return on Assets-65.78% Debt Debt-to-Equity RatioN/A Current Ratio4.85 Quick Ratio4.85 Sales & Book Value Annual Sales$80,000.00 Price / Sales183.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book0.55Miscellaneous Outstanding Shares26,440,000Free Float25,386,000Market Cap$14.65 million OptionableNot Optionable Beta2.87 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. David Alan Dodd (Age 73)Chairman, Pres & CEO Comp: $469.01kMr. Mark W. Reynolds CPA (Age 61)CPA, CFO & Corp. Sec. Comp: $348.2kDr. Mark J. Newman Ph.D. (Age 68)Chief Scientific Officer Comp: $364.17kDr. Harriet Latham Robinson Ph.D. (Age 85)Founder & Member of Scientific Advisory Board Dr. Kelly T. McKee Jr. (Age 73)M.D., M.P.H., Chief Medical Officer Jeffrey WelchHead of Process Devel. & Manufacturing OperationsDr. John W. Sharkey Ph.D. (Age 67)VP of Bus. Devel. More ExecutivesKey CompetitorsNeuroBo PharmaceuticalsNASDAQ:NRBOTonix PharmaceuticalsNASDAQ:TNXPAinosNASDAQ:AIMDImpel PharmaceuticalsNASDAQ:IMPLFrequency TherapeuticsNASDAQ:FREQView All CompetitorsInsidersKelly T Jr. MckeeBought 9,653 shares on 9/25/2023Total: $5,019.56 ($0.52/share)David A DoddBought 35,087 shares on 8/25/2023Total: $19,999.59 ($0.57/share)Mark ReynoldsBought 10,000 shares on 8/18/2023Total: $5,200.00 ($0.52/share)David A DoddBought 32,000 shares on 4/24/2023Total: $20,480.00 ($0.64/share)Mark ReynoldsBought 8,000 shares on 4/20/2023Total: $5,040.00 ($0.63/share)View All Insider Transactions GOVX Stock - Frequently Asked Questions Should I buy or sell GeoVax Labs stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GOVX shares. View GOVX analyst ratings or view top-rated stocks. What is GeoVax Labs' stock price forecast for 2023? 2 brokerages have issued 12 month price targets for GeoVax Labs' shares. Their GOVX share price forecasts range from $3.00 to $8.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 802.4% from the stock's current price. View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts. How have GOVX shares performed in 2023? GeoVax Labs' stock was trading at $0.6302 at the beginning of the year. Since then, GOVX shares have decreased by 12.1% and is now trading at $0.5541. View the best growth stocks for 2023 here. Are investors shorting GeoVax Labs? GeoVax Labs saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 676,300 shares, a decline of 14.9% from the August 31st total of 794,700 shares. Based on an average daily trading volume, of 345,200 shares, the short-interest ratio is presently 2.0 days. View GeoVax Labs' Short Interest. When is GeoVax Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our GOVX earnings forecast. How were GeoVax Labs' earnings last quarter? GeoVax Labs, Inc. (NASDAQ:GOVX) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.06. What is GeoVax Labs' stock symbol? GeoVax Labs trades on the NASDAQ under the ticker symbol "GOVX." How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GeoVax Labs' stock price today? One share of GOVX stock can currently be purchased for approximately $0.55. How much money does GeoVax Labs make? GeoVax Labs (NASDAQ:GOVX) has a market capitalization of $14.65 million and generates $80,000.00 in revenue each year. The company earns $-14,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. How can I contact GeoVax Labs? GeoVax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The official website for the company is www.geovax.com. The company can be reached via phone at (678) 384-7220, via email at investor@geovax.com, or via fax at 678-384-7281. This page (NASDAQ:GOVX) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.